Esperion Therapeutics, Inc. (ESPR) Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results
5/13/2014 7:11:48 AM
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and financial results for the first quarter ended Mar. 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by